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ABSTRACT
While smoking rates in the general adult population have declined, smoking
remains entrenched among individuals with opioid use disorder (OUD). Individuals with
OUD have an extremely high prevalence of smoking, experience poor cessation outcomes,
and bear a disproportionate burden of smoking-related adverse health consequences. Data
have also suggested that opioid-maintained (OM) smokers may experience a unique
response to nicotine including heightened reinforcement and potentially more severe
withdrawal when stopping smoking. Thus, this is a sub-group of smokers for which novel
harm reduction paradigms are urgently needed to reduce the burden of smoking. A
promising national policy is currently under consideration by the Food and Drug
Administration to decrease the nicotine content of cigarettes in an effort to reduce smoking
prevalence and smoking-related disease. It is critical to understand the extent to which
reduced nicotine content cigarettes (RNCCs) can attenuate tobacco withdrawal severity in
OM smokers as this has direct implications for the potential acceptability and uptake of
reduced nicotine cigarettes in this vulnerable subgroup.
The primary aims of this study were to rigorously examine the effects of OM
status on tobacco withdrawal and craving in response to participants’ usual brand cigarette
and research cigarettes that varied in nicotine content. Opioid-maintained (OM; n=65) vs.
non opioid-maintained (NOM; n=135) smokers completed 5 outpatient laboratory sessions
in which they smoked a single research cigarette varying in nicotine content (0.4, 2.4, 5.2,
15.8 mg/g of tobacco) or their usual brand cigarette under double-blind, acute abstinence
conditions. Participants completed the Minnesota Tobacco Withdrawal Scale before and
every 15 minutes for one hour following smoking each cigarette. As an exploratory aim,
we also examined the contribution of OM status to tobacco withdrawal in the context of
several other important characteristics associated with smoking vulnerability (e.g.,
depression, anxiety, education level). Repeated measures mixed model analyses were used
to examine all aims.
Across usual brand cigarettes and RNCCs, tobacco withdrawal and craving did
not differ as a function of OM status (p’s >.05). In multivariable models, nicotine dose,
time, depression, cigarette dependence, education level, but not OM status, consistently
predicted tobacco withdrawal and craving severity (p’s <.05). In particular, depression
severity, rather than OM status, was the strongest and most consistent predictor of
withdrawal and craving severity among the characteristics examined.
Despite prior data suggesting that OM smokers may respond differently to
nicotine and experience more severe withdrawal during reductions in nicotine intake, OM
smokers in this study responded favorably to RNCCs. These findings provide additional
support for the potential beneficial effects of a national nicotine reduction policy for
reducing the burden of smoking and smoking-related consequences among smokers with
concurrent OUD.
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CHAPTER 1: INTRODUCTION
1.1. Cigarette Smoking Among Individuals with Opioid Use Disorder
Despite considerable progress in tobacco control and prevention, cigarette
smoking remains the leading cause of preventable death and disability in the United
States (US) and is responsible for nearly 500,000 deaths each year (US Department of
Health and Human Services, 2014). While the prevalence of smoking among the general
US adult population has declined over the past several decades, it remains entrenched
among certain vulnerable populations. This is especially the case among individuals with
co-morbid substance use disorders (SUDs), non-SUD psychiatric disorders and
socioeconomic disadvantage, all of whom are overrepresented among current cigarette
smokers and bear a disproportionate burden of smoking-related disease (Hiscock, Bauld,
Amos, Fidler, & Munafò, 2012; Schroeder & Morris, 2010). For example, while
smoking prevalence has markedly decreased among individuals without SUDs, recent
nationally-representative data suggests that the prevalence of cigarette smoking in the
US is actually increasing among those with SUDs, excluding cannabis use disorders
(Weinberger et al., 2018).
Individuals with opioid use disorder (OUD) represent a population that is
particularly vulnerable to cigarette smoking and its adverse health effects. Prevalence of
smoking in this group is up to six-fold higher than the general population (84-94% vs.
15%, respectively)(Guydish et al., 2011, 2016; Hser, Hoffman, Grella, & Anglin, 2001;
Hser et al., 1994; Jamal, 2016; Nahvi, Richter, Li, Modali, & Arnsten, 2006; Richter,
Gibson, Ahluwalia, & Schmelzle, 2001), and the incidence of all-cause mortality is fourfold that of nonsmokers with OUD (Hser et al., 1994). Prevalence of smoking is also
1

higher among individuals in treatment for OUD compared to other SUDs (Guydish et al.,
2016, 2011). Finally, individuals with OUD often present with additional risk factors
that may further increase their risk for smoking and related adverse consequences,
including increased prevalence of comorbid non-SUD psychiatric disorders (e.g.,
depression and personality disorders) and socioeconomic disadvantage (e.g., limited
educational attainment), both of which are independently associated with increased
prevalence rates of smoking and poorer cessation outcomes (e.g., Higgins & Chilcoat,
2009; Hiscock et al., 2012; Kurti et al., 2016; Lasser et al., 2000).
Most individuals with OUD are aware of the health risks of smoking, express an
interest in quitting, and express interest in receiving smoking cessation services (Clarke,
Stein, McGarry, & Gogineni, 2001; Clemmey, Brooner, Chutuape, Kidorf, & Stitzer,
1997; Dunn, Sigmon, Reimann, Heil, & Higgins, 2009; Frosch, Shoptaw, Jarvik,
Rawson, & Ling, 1998; Kozlowski, Skinner, Kent, & Pope, 1989; Nahvi et al., 2006;
Richter et al., 2001; Sees & Clark, 1993). Despite this, responses to smoking cessation
interventions are notoriously poor in this group, with abstinence outcomes one-fourth
that of non-substance abusing smokers (Miller & Sigmon, 2015; Okoli et al., 2010;
Zirakzadeh, Shuman, Stauter, Hays, & Ebbert, 2013) and standard first-line
pharmacotherapies largely ineffective (Dunn et al., 2010; Miller & Sigmon, 2015; Okoli
et al., 2010; Zirakzadeh et al., 2013).

1.2. Nicotine Dependence in Smokers with OUD
While the specific factors contributing to the elevated smoking prevalence and
poor cessation outcomes among individuals with OUD are not well understood, one
2

possibility is that smokers with concurrent SUDs may present with more severe nicotine
dependence than smokers without co-occurring SUDs. Nicotine dependence (referred to
as tobacco use disorder in the Diagnostic and Statistical Manual of Mental Disorders, 5th
edition (DSM-5)) is characterized by tolerance, withdrawal and craving for nicotine
during abstinence, and loss of control over the amount or duration of use (American
Psychiatric Association, 2013).
Rates of nicotine dependence are two to four times higher in adults with current
SUDs compared to the general population (Grant, Hasin, Chou, Stinson, & Dawson,
2004). However, there is little research investigating nicotine dependence severity
among individuals with OUD specifically. We recently examined associations between
OUD and nicotine dependence using nationally representative cross-sectional data from
the National Survey on Drug Use and Health (Parker, Streck, & Sigmon, 2018). After
adjusting for baseline characteristics, adult daily smokers with OUD were roughly twice
as likely to be dependent on nicotine as compared to those without OUD. Smokers with
OUD also evidenced a greater severity of nicotine dependence compared to those without
OUD as measured by the Nicotine Dependence Severity Scale (NDSS; Shiffman, Waters,
& Hickcox, 2004). Importantly, greater baseline severity of nicotine dependence has
been shown to predict poorer cessation outcomes in the general smoker population
(Borland, Yong, O’Connor, Hyland, & Thompson, 2010; Breslau, Johnson, Hiripi, &
Kessler, 2001; Fagerstrom & Schneider, 1989; Kozlowski, Porter, Orleans, Pope, &
Heatherton, 1994; Transdisciplinary Tobacco Use Research Center et al., 2007; Vangeli,
Stapleton, Smit, Borland, & West, 2011).

3

1.3. Tobacco Withdrawal in Smokers with OUD
Tobacco withdrawal, a hallmark feature of nicotine dependence, may also play a
role in opioid-dependent individuals’ smoking behavior.

Given the high rates of

smoking, nicotine dependence and poor cessation outcomes in this population, for
example, one might expect to find elevated withdrawal severity upon discontinuation of
smoking.

In the general smoker population, individuals who experience greater

withdrawal upon quitting smoking are at increased risk for relapse (Allen, Bade,
Hatsukami, & Center, 2008; American Psychiatric Association, 2013; Hughes, 2007a;
Patten & Martin, 1996; West, Hajek, & Belcher, 1989).
The extant data do suggest elevated incidence and severity of tobacco withdrawal
among smokers with concurrent SUDs (Breslau, Kilbey, & Andreski, 1992; Hughes,
1996; Weinberger, Desai, & McKee, 2010). However, there is a paucity of empirical
data on tobacco withdrawal among smokers with OUD, and the limited studies thus far
have produced mixed results. To our knowledge, only three published studies have
evaluated tobacco withdrawal among smokers receiving methadone or buprenorphine
maintenance for treatment of OUD. In an early report on this topic, Story and Stark
(1991) examined the efficacy of a methadone dose increase as a pharmacological adjunct
to a cognitive-behavioral treatment for smoking cessation.

Methadone-maintained

participants (n=33) were randomly assigned to either an experimental group which
received a 20% methadone dose increase for a 28-day experimental period or to a control
group that received a one milligram dose increase for the same duration. There were no
significant differences between experimental groups in cigarette abstinence rates, though
participants receiving the methadone dose increase did report more tobacco withdrawal
4

symptoms than controls. However, the findings were limited by a sizeable amount of
continued smoking in both experimental groups.
In a more recent study, Elkader and colleagues examined methadone and nicotine
interactions among methadone-maintained patients (n=40) during trough and peak
methadone dose conditions using a within-subject design (Elkader, Brands, Selby, &
Sproule, 2009). Participants rated their tobacco withdrawal symptoms before and after
self-administering nicotine (own-brand cigarettes, nicotine gum or placebo gum,
depending on the study day) following 12 hours of smoking abstinence under two
methadone dosing conditions: Before they ingested their daily methadone dose (at trough
methadone blood levels) and 3 hours following methadone administration (peak
methadone blood levels). In that study, there was a main effect of methadone dose
condition on tobacco withdrawal severity, whereby tobacco withdrawal was attenuated
when methadone was at peak (vs. trough) levels.
Finally, we recently examined the timecourse and severity of tobacco withdrawal
among methadone- or buprenorphine-maintained (n=47) vs. non-SUD smokers (n=25),
all of whom completed one of several two-week studies involving daily visits for
biochemical monitoring and delivery of financial incentives contingent on smoking
abstinence (Streck, Heil, Higgins, Bunn, & Sigmon, 2018). To prevent ongoing smoking
from confounding evaluations of withdrawal, we examined withdrawal severity among
the subset of participants who achieved biochemically-verified smoking abstinence.
While opioid-maintained smokers presented with significantly higher levels of
withdrawal at study intake (when smoking as usual) relative to the non-SUD smokers,
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the two groups had remarkably similar profiles of withdrawal across the two-week period
of smoking abstinence.
In summary, while tobacco withdrawal severity is associated with relapse to
smoking and is an important component of continued addiction to cigarettes in the
general smoker population (Allen et al., 2008; Patkar, Vergare, Batra, Weinstein, &
Leone, 2003; West et al., 1989), its potential role among smokers with OUD remains
unclear. Of the three studies that have examined withdrawal among opioid-dependent
smokers, one suggested that opioid agonists may be associated with more severe
withdrawal, one suggested that opioids may attenuate withdrawal, and one found no
difference in withdrawal between opioid-dependent and non opioid-dependent smokers.
The methodological differences across these studies may account for these mixed
findings, as they employed different scientific designs and analytic approaches (e.g.,
within-subject vs. cross-sectional designs, evaluating withdrawal only among abstinent
vs. all smokers, evaluating smoking during stable vs. acute changes in opioid dose).
Further, none of the prior studies utilized double-blind nicotine administration or
examined multiple nicotine doses, and all generally focused on withdrawal following
abrupt discontinuation of smoking.

1.4. Reducing the Nicotine Content of Cigarettes
There is an urgent need to understand the severity of withdrawal experienced by
vulnerable smokers under conditions of reduced nicotine intake. A national policy is
currently under consideration to reduce smoking prevalence and smoking-related disease
in the US by decreasing the nicotine content of cigarettes below the threshold necessary
6

to establish and sustain nicotine dependence (Benowitz & Henningfield, 1994; Gottlieb
& Zeller, 2017). The 2009 Family Smoking Prevention and Tobacco Control Act granted
the US Food and Drug Administration (FDA) regulatory authority over cigarettes and
other tobacco products (111th Congress, 2009). That legislation includes the authority
to reduce the maximal nicotine content of cigarettes, though not completely eliminate
nicotine, if doing so benefits public health. This policy is based on the overwhelming
scientific evidence that nicotine is the constituent in cigarette smoke that promotes
repeated use and eventual addiction (Stolerman & Jarvis, 1995; US Department of Health
and Human Services, 2014) and the decades of research demonstrating that reducing the
amount of nicotine in cigarettes reduces their addiction potential (Benowitz &
Henningfield, 2013; Boren, Stitzer, & Henningfield, 1990; Shahan, Bickel, Madden, &
Badger, 1999). Thus, reductions in nicotine content may reduce smoking prevalence and
related disease by disrupting initiation of smoking by new users and increasing cessation
rates among current smokers. Well-controlled studies have demonstrated that use of
reduced nicotine content cigarettes (RNCCs) in the general smoker population is
associated with reductions in smoking rates, nicotine exposure, dependence and toxicant
exposure, as well as increases in smoking abstinence (Benowitz et al., 2007, 2009;
Donny, Houtsmuller, & Stitzer, 2007; Donny et al., 2015; Hatsukami, Hertsgaard et al.,
2013; Hatsukami, Kotlyar et al., 2010).

Further, in a recently published report,

simulation modeling was used to estimate the effect of a national nicotine reduction
policy on the prevalence of tobacco use, tobacco-related mortality and life-years gained
(Apelberg et al., 2018). Not only would lowering the nicotine content of cigarettes lead
to substantial reductions in tobacco use and smoking-related mortality, but the authors
7

projected that such a policy would result in 5 million additional adult smokers quitting
smoking by 2020.
While these data are promising, the prior studies on RNCCs have excluded
individuals with SUDs and non-SUD psychiatric disorders and instead focused on stable,
generally “healthy” smokers.

Considering their suboptimal response to standard

smoking cessation treatments and substantial burden experienced from smoking, it is
important to understand whether smokers with concurrent SUDs or other vulnerabilities
may respond differently to RNCCs. Indeed, the US FDA’s Center for Tobacco Products
has identified these smokers as a priority population in whom more tobacco regulatory
research is needed (US Department of Health and Human Services, 2017). With regard
to opioid-dependent smokers specifically, given the scientific evidence that opioid
agonist medications may increase the reinforcing effects of nicotine administration
(Chait & Griffiths, 1984; Mello, Lukas, & Mendelson, 1985; Mello, Mendelson, Sellers,
& Kuehnle, 1980), it is critical to ensure that these smokers will not compensate for
reduced nicotine levels by increasing their smoking rates or experience a unique profile
of subjective effects following use of RNCCs. Tobacco withdrawal is a subjective effect
with direct implications for the potential acceptability and safety of RNCCs among
consumers (Donny et al., 2014). While promising data suggest that RNCCs may
attenuate tobacco withdrawal severity (Table 1), very little is known about the ability of
RNCCs to attenuate tobacco withdrawal severity in smokers with co-occurring other
vulnerabilities including OUD.

8

1.5. Evaluating RNCCs among Vulnerable Smokers
To our knowledge, only two studies have evaluated tobacco withdrawal among
vulnerable smoker populations and only one of those included participants with SUDs.
In an initial small, within-subject study, the effects of smoking a reduced nicotine
cigarette, nicotine replacement therapy, and a usual brand cigarette were examined
among individuals with schizophrenia (n=30) versus those without a psychiatric disorder
(n=26) (Tidey, Rohsenow, Kaplan, Swift, & Ahnallen, 2013). While participants with
schizophrenia reported greater tobacco withdrawal severity compared to those without
psychiatric disorders across all study conditions, the RNCC was as effective at
attenuating tobacco withdrawal symptoms as participants’ usual brand cigarette.
The second and more recent study was completed by our research group (Higgins
et al., 2017). To our knowledge, this has been the only trial to date to examine the acute
effects of cigarettes varying in nicotine content among opioid-maintained smokers.
Using a multi-site, double-blind, within-subject design, we sought to investigate the acute
effects of RNCCs among three populations of vulnerable smokers (N=169): opioidmaintained individuals (n=60), individuals with affective disorders (n=56), and
socioeconomically-disadvantaged women of childbearing age (n=53).

Across 14

outpatient laboratory sessions, participants were acutely exposed to research cigarettes
containing nicotine doses that ranged from levels below the proposed addiction threshold
(Benowitz & Henningfield, 1994) to those consistent with commercially available
cigarettes (i.e., 0.4, 2.4, 5.2, and 15.8 mg/g of tobacco), as well as to their usual brand
cigarette. All study sessions were conducted following a brief period of smoking
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abstinence (approximately 6-8 hours of abstinence or breath carbon monoxide levels
<50% of baseline).
The relative reinforcing effects of smoking (i.e., addiction potential) decreased as
an orderly function of decreasing the nicotine content of cigarettes in all three vulnerable
populations. In terms of the withdrawal severity experienced and, importantly, the extent
to which RNCCs attenuated smokers’ withdrawal following acute abstinence, all nicotine
doses significantly reduced tobacco withdrawal severity, with higher magnitude
reductions seen at the higher dose cigarettes.
The primary outcomes in that study (e.g., reinforcing efficacy as evaluated by
concurrent choice preference testing and behavioral economic simulation tests,
compensatory smoking) were reported in aggregate across the vulnerable smoker subgroups examined given the similarities among smoker groups on those measures. With
regard to withdrawal, while opioid-maintained smokers reported levels of tobacco
withdrawal that were higher than the socioeconomically-disadvantaged women and
similar to smokers with affective disorders, how tobacco withdrawal severity changed
over time among opioid-maintained (OM) smokers and whether there were differences
in withdrawal as a function of the nicotine doses were not examined. Additionally, how
the other characteristics representative of vulnerability to smoking (e.g., depression,
educational attainment) may affect withdrawal severity and contribute to OM smokers’
response to the cigarettes in this trial has not been evaluated.

10

1.6. Aims/Hypotheses
We sought to comprehensively evaluate tobacco withdrawal severity in response
to acute exposure to RNCCs among OM smokers under conditions of double-blind
nicotine administration, acute abstinence and across multiple nicotine doses.

Our

overarching aim was to better understand the ability of cigarettes varying in nicotine
content to attenuate tobacco withdrawal severity in OM compared to non opioidmaintained (NOM) smokers.
In Aim 1, we examined the association between OM status (i.e., opioidmaintained participants vs. all other study participants) and tobacco withdrawal in
response to participants’ usual brand cigarette. We hypothesized that OM smokers would
experience greater severity of tobacco withdrawal than NOM smokers.
In Aim 2, we examined the association between OM status and tobacco
withdrawal in response to the four research cigarette doses (0.4, 2.4, 5.2, 15.8 mg/g)
under double-blind conditions. We hypothesized that OM status would moderate the
relationship between nicotine dose and withdrawal severity. Specifically, we anticipated
that higher nicotine dose research cigarettes would reduce tobacco withdrawal severity
to a greater extent among NOM smokers vs. OM smokers.
As an exploratory Aim 3, we also examined the contribution of other
characteristics previously associated with smoking vulnerability (e.g., depression,
anxiety, education level) on acute withdrawal in response to cigarettes varying in nicotine
content, as well as how each vulnerability was associated with tobacco withdrawal over
and above OM status. This research question stemmed in part from the previouslydiscussed observation of sub-group differences in tobacco withdrawal severity in the
11

parent trial in which more severe withdrawal was seen among OM smokers and those
with affective disorders relative to disadvantaged women (Higgins et al., 2017) (Figure
1), suggesting that project-specific inclusion criteria such as anxiety, depression and
education level were particularly important to consider. It also drew from the larger
literature showing that non-SUD psychiatric disorders (e.g., mood, anxiety, personality
disorders) and socioeconomic disadvantage (e.g., level of educational attainment) are not
only independently associated with elevated smoking prevalence and lower quit rates
compared to the general population, but also co-occur at high rates in populations with
OUD (Higgins, 2016; Higgins & Chilcoat, 2009; Hiscock et al., 2012; Lasser et al., 2000;
Parsells, Kelly et al., 2008; SAMHSA, 2015; Schroeder, 2016; Strain, 2002; US
Department of Health and Human Services, 2014).

Further, relevant to tobacco

withdrawal specifically, there is strong evidence in the literature that non-SUD
psychiatric disorders are associated with a greater incidence and severity of tobacco
withdrawal (Covey, Glassman, & Stetner, 1990; Morrell, Cohen, & al’Absi, 2008;
Pomerleau, Marks, & Pomerleau, 2000; Smith, Homish, Giovino, & Kozlowski, 2014;
Weinberger et al., 2010). Emerging research has also suggested that this pattern of
elevated withdrawal severity may extend to those with socioeconomic disadvantage
(Harwood, Salsberry, Ferketich, & Wewers, 2007; Hiscock et al., 2012; Marmot &
Wilkinson, 2005; Wiltshire, Bancroft, Parry, & Amos, 2003). Considering the potential
synergistic interaction among risk factors that may influence tobacco withdrawal severity
in OM smokers, in Aim 3, we examined how OM status may contribute to withdrawal in
the larger context of other smoking-related vulnerabilities that so often co-occur in
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opioid-dependent smokers. As this represented an exploratory aim, we did not propose
a directional hypothesis for this outcome.

1.7. Summary
Taken together, we are at a critical moment in tobacco regulatory science and
tobacco control with the FDA actively considering reducing the nicotine levels of
cigarettes as a national harm reduction policy. Scientific efforts are urgently needed to
understand the impact of such a nicotine reduction policy on the populations of smokers
with co-occurring vulnerabilities that smoke the majority of the cigarettes in the US
(Lasser et al., 2000). An improved understanding of the ability of reduced nicotine
cigarettes to attenuate tobacco withdrawal in opioid-maintained smokers stands to
directly inform FDA policy decisions and advance efforts to reduce the disproportionate
burden of smoking in this population.

13

CHAPTER 2: METHODS
2.1. Participants
Participants were 202 daily smokers (65 with affective disorders, 66 with OUD,
71 socioeconomically-disadvantaged women).

Participants were recruited though

advertisements placed on Facebook, bulletin boards throughout the community, buses
and local newspapers at Johns Hopkins University, Brown University and the University
of Vermont. The study was approved by the respective universities’ Institutional Review
Boards, and all participants provided written informed consent. Parent study inclusion
criteria required that participants were >18 years of age, reported smoking >5 cigarettes
per day for the past year and provided an expired breath carbon monoxide (CO) level of
>8 particles per million (ppm).

All participants had to provide a negative urine

toxicology test for illicit drugs other than marijuana. Exclusion criteria included an
intention to quit smoking within the next 30 days, significant use (>9 days) of other
tobacco products in the past 30 days, currently pregnant or trying to become pregnant,
breastfeeding, exclusive use of “roll your own” cigarettes, or current suicidal ideation or
a recent suicide attempt.
Additionally, there were several additional project-specific inclusion (Figure 2)
and exclusion criteria. Participants in the OM smokers project were females and males
ages 18-70 who were currently receiving methadone or buprenorphine maintenance
treatment. They were required to be stable on their maintenance dose which was defined
as no change in dose and <30% urine toxicology samples testing positive for illicit drug
use in the past month. Participants in the affective disorders project were females and
males ages 18-70 years who met criteria for current or past year major depressive
14

disorder, dysthymic disorder, generalized anxiety disorder, post-traumatic stress
disorder, obsessive compulsive disorder, specific phobia or panic disorder with or
without agoraphobia based on the MINI International Neuropsychiatric Interview for
DSM-IV (Sheehan et al., 1998).

Finally, participants in the project with

socioeconomically-disadvantaged women were females, ages 18-44, with less than an
associate’s degree.

2.2. Research Cigarettes
Research cigarettes were manufactured by the 22nd Century Group (Clarence,
NY) and included four nicotine content dose conditions: 0.4, 2.4, 5.2, and 15.8
milligrams of nicotine per gram (mg/g) of tobacco (Donny et al., 2015; Higgins et al.,
2017). The research cigarettes were identical in appearance to one another and to
commercially-available cigarettes but varied in nicotine content. The 15.8 mg/g cigarette
was designed to have a nicotine content similar to commercially available cigarettes, the
0.4 mg/g cigarette fell below the hypothesized threshold of addiction (Benowitz &
Henningfield, 1994), and the 5.2 and 2.4 mg/g cigarettes represented reduced nicotine
content cigarettes. All sessions involving research cigarettes took place under doubleblind conditions with each cigarette dose being represented by a letter code for blinded
research staff.

2.3. Procedures
The parent study consisted of 14 experimental sessions using a within-subject
design. All sessions were conducted under conditions of brief smoking abstinence
15

(breath CO<50% of baseline). Participants were instructed to abstain from smoking for
at least six to eight hours prior to the session so as to meet the breath CO criteria. At the
start of each session, participants took two puffs from their usual brand cigarette in order
to equate the time since last cigarette across study participants (Henningfield & Griffiths,
1981). Thirty minutes following the two puffs marked the beginning of the experimental
session. During this 30-minute break participants completed the Minnesota Tobacco
Withdrawal Scale (MTWS; Hughes & Hatsukami, 1986; described in greater detail
below) and the Questionnaire on Smoking Urges-Brief (QSU; Cox, Tiffany, & Christen,
2001) to assess baseline levels of tobacco withdrawal and craving, respectively, prior to
exposure to the research cigarettes. The 14 study sessions were divided into three study
phases. As Phase 1 is the focus of this project, Phases 2 and 3 will only be described
briefly here (Higgins et al., 2017).
Study Intake Visit (Session 0). Participants presented for an in-person screening
visit to determine their eligibility. Intake screening measures relevant to this dissertation
included smoking and demographic characteristics (e.g., average cigarettes smoked per
day, cigarette dependence severity, education level, gender, age). The Fagerström Test
for Cigarette Dependence (FTCD) is a 7-item measure to assess cigarette dependence
with total scores reported as the sum of scores on the first 6 items of the measure
(Fagerström, 2012). Higher scores are suggestive of higher levels of dependence. The
Beck Depression Inventory (BDI; Beck, 1996) and the Overall Anxiety Severity and
Impairment Scale (OASIS; Norman, Cissell, Means-Christensen, & Stein, 2006) were
used to assess depression and anxiety, respectively. The BDI is a 21-item measure which
screens for depression severity in the past two weeks. Items are rated on a 0-3 scale with
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total scores ranging from 0 to 63. A total score is computed based on summing scores
on all items of the measure. Research suggests that a valid BDI cut-off to use in the
research setting is a score of 17 or greater which is indicative of clinically meaningful
depression and a potential need for treatment (Beck, 1996; Sprinkle et al., 2002). The
OASIS is a 5-item screening measure assessing anxiety severity in the past week. Items
are rated on a 0-4 scale with total scores ranging from 0 to 20. Finally, OM smokers also
provided additional information on their opioid maintenance medication (e.g.,
methadone or buprenorphine, current dose).
Baseline Session (Session 1) and Study Phase 1 (Experimental Sessions 2-5).
Session 1 (i.e., baseline session) served as an orientation or practice session
wherein participants smoked their usual brand cigarette using the study procedures that
would be in place for remaining sessions. Thereafter during Sessions 2-5, participants
sampled each research cigarette under double-blind, acute abstinence conditions with
cigarettes presented in a random order (Figure 3). Participants smoked one of the four
research cigarettes per session in a random order. In all sessions, participants were
instructed to smoke the research cigarettes as they would smoke their usual brand
cigarette, but to do so through a plastic cigarette holder connected to a device that
recorded measures of smoking topography (Lee, Malson, Waters, Moolchan, &
Pickworth, 2003).
After smoking the cigarette, participants then completed a battery of self-reported
measures including the Cigarette Purchase Task (CPT; MacKillop et al., 2008), Modified
Cigarette Evaluation Questionnaire (mCEQ; Cappelleri et al., 2007), QSU and MTWS,
which measure hypothetical cigarette purchasing behavior, the degree to which people
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experience the reinforcing effects of cigarettes, cigarette craving and tobacco withdrawal,
respectively. The MTWS and the QSU were administered to participants every 15
minutes for an hour following the completion of the research cigarette in each session.
At each 15-minute timepoint, research staff also measured expired breath CO levels using
a hand-held device (CoVita, Haddonfield, NJ).
Study Phases 2 and 3. As noted above, Phases 2 and 3 were not a focus of this
dissertation and thus are only briefly described here. During Phase 2 (Sessions 6-11),
the relative reinforcing effects of the range of nicotine doses were evaluated using a
concurrent choice testing paradigm, in which participants were instructed to choose
which cigarette they preferred to smoke when both cigarettes were available at an equal
response cost. In Phase 3 (Sessions 12-14), participants chose between cigarette dose
pairs, with a focus on the highest and the lowest dose cigarettes. The highest dose
cigarette had a higher response cost and was available on an increasing progressive ratio
schedule.

2.4. Outcome Measures
The primary outcome measure was the Minnesota Tobacco Withdrawal Scale
(MTWS; Hughes & Hatsukami, 1986), a 15-item self-report measure of tobacco
withdrawal. Each item is rated on a 5-point ordinal scale (0=none, 1=slight, 2=mild,
3=moderate, 4=severe). The MTWS includes seven DSM-5 items (anger/irritability/
frustration, anxiety/nervousness, difficulty concentrating, impatience/restlessness,
increased appetite/hunger, insomnia/awakening at night, depressed mood/sad) that are
averaged to construct a single withdrawal severity score (i.e., MTWS Total score).
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Additionally, a Desire to Smoke item is typically analyzed separately as a measure of
craving (Hughes & Hatsukami, 1998). The scientific literature supports the reliability
and validity of the MTWS in measuring withdrawal and craving severity in the general
smoker population (Cappelleri et al., 2005; Etter & Hughes, 2006; Hughes, 2007; Javitz,
Lerman, & Swan, 2012; Piper, 2015; Piper, McCarthy, & Baker, 2006; Toll, O’Malley,
McKee, Salovey, & Krishnan-Sarin, 2007; Weinberger et al., 2007; West, Ussher, Evans,
& Rashid, 2006).
During each session, the MTWS was administered following acute (i.e., 6-8
hours) abstinence and after taking the two puffs of the usual brand cigarette (Time 0; Presmoking baseline). MTWS administration was then repeated every 15 minutes for an
hour following completion of the assigned research cigarette (Times 1-4). The dependent
variables for this dissertation were the MTWS Total and Desire to Smoke scores across
these five timepoints (Times 0-4) during the baseline session and Phase 1 of the study
(Figure 3).

2.5. Statistical Analyses
This secondary analysis focused on participants who completed Phase 1 of the
parent study (N=202). Of these, we excluded two participants as one participant had
missing BDI and OASIS data from baseline and another participant had missing OASIS
data at baseline (N=200). While one participant had missing MTWS data at a single
timepoint for one session (45-minute point in Session 1), they were still included in the
analyses.
Demographic, psychiatric and smoking characteristics were examined by OM
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status using chi-square or Fisher’s Exact tests for categorical variables and t-tests or
Wilcoxon Rank Sum tests for continuous variables. To address Aim 1, MTWS Total
scores and Desire to Smoke scores were examined during Session 1 (usual brand cigarette
baseline session) using mixed-model repeated-measures (RM) analyses. Time (i.e., presmoking baseline and 15, 30, 45, and 60 minutes post-smoking the cigarette) was
included in the model as a within-subject factor and OM status, dichotomized (yes vs
no), was included as an across-subject factor. Study site was included as a random factor
in this model.
For Aim 2, we similarly performed a mixed-model RM analysis. Time (i.e., presmoking baseline and 15, 30, 45, and 60 minutes after smoking the cigarette) and research
cigarette dose (0.4, 2.4, 5.2, 15.8 mg/g) were included as within-subject factors and OM
status as an across-subject factor. Study site was included as a random effect in this
model.
In exploratory Aim 3, we examined the contribution of participant characteristics
reflective of smoking vulnerability to tobacco withdrawal using multivariable mixedmodel RM analyses. As with Aim 2, time and nicotine dose were within-subject factors
and OM status was an across-subject factor. Variable selection for construction of the
final model was based on both bivariate testing and the empirical literature. Age, race,
gender, employment status, marital status, FTCD total score, cigarettes smoked per day,
BDI and OASIS were included in preliminary models as there was evidence that they
were associated with withdrawal based on bivariate testing (p<.10). Education level, age
started smoking regularly and screening CO level were forced into preliminary models
based on the literature. We chose to use a dichotomous variable for BDI in our models
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for ease of interpretation using a commonly established cut-off of 17 to distinguish those
with clinically meaningful depression levels (Beck, 1996; Sprinkle et al., 2002).
Furthermore, in preliminary models, we forced OM status into models and added
additional characteristics sequentially to determine how each was associated with
tobacco withdrawal over and above OM status. We present final multivariable models
in two ways: First, with only the variables that were significant predictors of tobacco
withdrawal; second, with all significant predictors of withdrawal with OM status retained
in the model, regardless of significance, as it was a main focus of the current study.
Finally, supplemental analyses were conducted to examine changes in withdrawal
and craving in response to nicotine dose, using methods commonly employed in
behavioral pharmacology research (e.g., Iversen & Lattal, 1991; Sobel, Sigmon, &
Griffiths, 2004). First, we examined peak effects of the research cigarette nicotine doses’
ability to attenuate withdrawal. Specifically, for Aims 1 and 2, we computed the peak
change from baseline in withdrawal (i.e., difference between the pre-smoking baseline
timepoint and the minimum withdrawal score seen between 15 and 60 minutes postsmoking) for each participant, then averaged across participants to form the dependent
measure in mixed models. In these models, OM status was the primary independent
variable and, for Aim 2, dose was also included in the model. Second, sensitivity
analyses were conducted for Aims 2 and 3, examining area under the time curve (AUC)
of repeated MTWS scores as the dependent variable to determine whether AUC analysis
differs from repeated measures mixed modeling in explaining withdrawal scores over
time. Finally, we compared data from participants who completed Phase 1 of the study
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and were included in this secondary analysis (n=200) to those who dropped out (n=35)
on our variables of interest to determine any potential biases due to attrition.
All post-hoc testing used a Bonferroni adjustment for multiple comparisons. All
analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
significance was defined as p<.05.
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Statistical

CHAPTER 3: RESULTS
3.1. Participant Characteristics
Baseline demographic and smoking characteristics by OM status are presented in
Table 2. Briefly, OM smokers were on average 41 years of age, 23% unemployed,
smoked an average of 16 cigarettes per day and presented with an FTCD score of 5,
suggesting moderate tobacco dependence. Compared to NOM smokers, OM smokers
were older, less likely to be female, more likely to be nicotine dependent, and had lower
levels of anxiety and depression. Employment and marital status were also significantly
different between the groups.

3.2. Aim 1
Mean tobacco withdrawal severity scores (i.e., MTWS Total scores) during the
baseline (usual brand cigarette) Session 1 did not differ as a function of OM status (F(1,
185)=0.69, p=.41; Figure 4, upper panel). There also was no evidence of an interaction
between OM status and time on mean withdrawal scores during the baseline session (F(4,
791)=1.48, p=.21).
A similar pattern was seen with cigarette craving (i.e., the Desire to Smoke item
of the MTWS). Craving severity following smoking the usual brand cigarette did not
differ as a function of OM status (F(1, 198)=0.19, p=.66; Figure 4, lower panel), nor was
there a significant interaction between OM status and time on reports of cigarette craving
(F(4, 791)=1.53, p=.19).
For both withdrawal and craving, there was a significant main effect of time (F(4,
795)=52.80, p<.001; F(4, 795)=62.82, p<.001, respectively) with MTWS scores
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decreasing 15 minutes after smoking the usual brand cigarette and then gradually
increasing over time (i.e., across the remaining 45 minutes of the hour following
smoking).

3.3. Aim 2
When examining tobacco withdrawal during exposure to cigarettes varying in
nicotine content during Sessions 2-5, withdrawal severity did not differ as a function of
OM status (F(1, 175)=1.65, p=.20; Figure 5, upper panel). There also was no significant
interaction on the withdrawal outcome between OM status and nicotine dose (F(3,
591)=2.15, p=.09) or among OM status, time and nicotine dose (F(19, 3146)=1.35,
p=.14).
Similarly, there was no main effect of OM status on craving (F(1, 198)=2.76,
p=.10), no OM by nicotine dose interaction (F(3, 591)=2.34, p=.07), and no OM status
by time by nicotine dose interaction (F(19, 3146)=1.57, p=.06)(Figure 5, lower panel).
Consistent with the parent trial report (Higgins et al., 2017), there were significant
dose x time interactions on both withdrawal and craving severity in Phase 1 (F(12,
2386)=3.00, p<.001; F(12, 2385)=6.42, p<.001, respectively) with both outcomes
decreasing over time following smoking the research cigarettes and then gradually
returning to baseline levels over time, with higher magnitude reductions seen at higher
dose cigarettes.

Finally, there were also main effects of dose and time for both

withdrawal and craving measures (MTWS Total score: Dose F(3, 591)=4.5, p<.001, time
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F(4, 793)=83.62, p<.001; MTWS Desire to Smoke: Dose F(3, 591)=7.04, p<.001, time
F(4, 793)=130.93, p<.001).

3.4. Exploratory Aim 3
In exploratory Aim 3, we examined the contribution of OM status in relation to
other participant characteristics reflective of smoking vulnerability to tobacco
withdrawal and craving. Regarding withdrawal during the baseline Session 1 (i.e., usual
brand cigarette session), time, BDI and FTCD, but not OM status, were significantly
associated with tobacco withdrawal severity (Table 3, upper right panel). In a final model
that only included significant predictors of withdrawal severity, time, BDI score and
FTCD total score were significant predictors in this usual brand cigarette session (Table
3, upper left panel). In these models, individuals with clinically meaningful depression
(i.e., BDI total score >17) evidenced greater levels of withdrawal severity compared to
those without clinically elevated depression (i.e., BDI total score <17) (mean
difference=0.60; p<.001). Similarly, those with higher levels of baseline cigarette
dependence as measured by the FTCD also evidenced greater withdrawal severity (β(SE)
=0.06 (0.02), p<.01) in response to the usual brand cigarette.
During Sessions 2-5 evaluating research cigarettes with varying nicotine content,
the significant predictors of withdrawal were nicotine dose, time, the dose x time
interaction, BDI, education level, race, FTCD total score and OM status (Table 3, lower
right panel). While OM status was a significant predictor of withdrawal in this model
(F(1,191)=6.65; p=.01), it was subsequently dropped from the final model as there was
evidence of confounding between OM status and BDI. Specifically, not only was OM
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status not a significant predictor of withdrawal in any of the prior models, but there were
significant correlations between BDI scores and OM status (Spearman correlation=
-0.26, p<.001). With regards to differences by race, Non-Latino White participants had
higher withdrawal than Non-Latino Black participants (mean difference=0.39; p=0.01).
The resulting final model predicting withdrawal included nicotine dose, time, the dose x
time interaction, BDI, FTCD scores, and education level (Table 3, lower left panel). In
this model, higher depression at baseline (mean difference=0.64, p<.001) and higher
cigarette dependence (β(SE)=0.07(0.02), p<.01) were predictive of greater tobacco
withdrawal. Lower educational attainment (i.e., high school education vs. some college
and some college vs. associate’s degree or higher) also predicted greater withdrawal in
response to the cigarettes varying in nicotine content (mean differences=0.29 and 0.33,
respectively; p’s<.05).
With regard to craving, time, BDI, FTCD and screening CO level, but not OM
status, were significantly associated with craving during the baseline Session 1 (i.e., usual
brand cigarette session) (Table 4, upper right panel). The final model of variables
significantly predicting craving during this session included time, BDI, FTCD and
screening breath CO level (Table 4, upper left panel).

Higher baseline levels of

depression (mean difference=0.32, p=0.01), cigarette dependence (β(SE)=0.14 (0.03);
p<.001) and breath CO levels at study intake (β(SE)=0.02 (0.01); p<.01) were predictive
of greater craving severity.
Finally, in terms of craving during exposure to cigarettes varying in nicotine
content, significant predictors of craving were nicotine dose, time, dose x time
interaction, FTCD total score, the OM status x time interaction, but not OM status (Table
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4, lower panel). The significant interaction between time and OM status was primarily
driven by between-group differences in mean craving at the last time point (i.e., an hour
after smoking the research cigarette) (adjusted means=2.95 vs. 2.63 for OM vs. NOM,
respectively; p=.04); however, none of the comparisons of means at each timepoint
between groups differed after Bonferroni adjustment (p’s=1.0), suggesting that
confounding of multiple comparisons may have driven the significant interaction seen in
the final model.

3.5. Additional Analyses
As previously noted, several additional analyses were conducted to examine peak
change from the pre-smoking baseline timepoint for withdrawal and craving in baseline
Session 1 and across Sessions 2-5. We also examined AUC analyses to validate the
results from mixed modeling. Finally, to address attrition, we compared those who did
and did not complete Phase 1 on our variables of interest to determine any potential biases
due to attrition.
When examining peak change from the pre-smoking baseline timepoint during
baseline Session 1 (related to Aim 1), there were no differences by OM status for MTWS
Total scores (F(2, 197)=0.41, p=.52) or Desire to Smoke (F(2, 197)=0.06, p=.81). A
similar pattern was observed when examining peak change during Sessions 2-5 (related
to Aim 2), with no differences by OM status for MTWS Total scores (F(1, 198)=0.56,
p=.46) or Desire to Smoke (F(1, 198)=0.11, p=.75). There were main effects of nicotine
dose on peak change in MTWS Total (F(3, 595)=4.04, p<.001) and Desire to Smoke
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scores (F(3, 595)=14.17, p<.001), with higher nicotine doses resulting in a larger
magnitude reduction in MTWS scores from the pre-smoking baseline timepoint.
Regarding AUC analyses across the multiple nicotine doses evaluated in Sessions
2-5, there was neither an effect of OM status (F(1, 171)=1.68, p=.20) nor an OM status
by nicotine dose interaction (F(3, 587)=2.37, p=.07) on MTWS Total score AUC. There
also were no main effects of OM status on Desire to Smoke AUC (F(1, 198)=2.61,
p=.11), though there was a significant OM status by nicotine dose interaction (F(3,
587)=2.85, p=.04). Upon probing this interaction, we determined that it was primarily
driven by between-group differences in mean craving AUC at the 5.2 mg/g cigarette
(adjusted means=10.67 vs. 8.83 for OM vs. NOM, respectively; p=.01)(Figure 5);
however, this difference was no longer significant after Bonferroni adjustment for
multiple comparisons (p=.15). Thus, overall, AUC analyses produced similar results to
the repeated measures mixed model analyses, with no robust effects of OM status on
tobacco withdrawal or craving scores via the MTWS. In both models predicting tobacco
withdrawal and craving AUC in Phase 1, there were main effects of nicotine dose (F(3,
587)=4.74, p<.01; F(3, 587)=8.73, p<.001, respectively) consistent with repeated
measures mixed model analyses.
Additional analyses for exploratory Aim 3 used AUC to examine tobacco
withdrawal and craving in the above multivariable models and produced similar results
to repeated measures mixed modeling, again suggesting that OM status does not
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contribute significantly to withdrawal or craving across usual brand cigarettes or
cigarettes varying in nicotine content (Table 5).
Finally, our completer analysis suggested that individuals who did (n=200) vs. did
not (n=35) complete Phase 1 were similar on nearly all demographic and smoking
characteristics with the exception of higher cigarettes smoked per day reported at study
intake among individuals who did not vs. did complete Phase 1 (means=18 vs. 15 average
cigarettes/day, respectively; p=.05) (Table 6).
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CHAPTER 4: DISCUSSION
4.1. Effects of Opioid Maintenance and Other Vulnerabilities on
Tobacco Withdrawal
Smokers with concurrent opioid use disorder have an extremely high prevalence
of smoking, experience poor cessation outcomes, and bear a disproportionate burden of
smoking-related adverse health consequences. This is a subgroup of smokers for whom
novel harm reduction paradigms are urgently needed to reduce the burden of smoking. A
promising national policy is currently under consideration by the FDA to decrease the
nicotine content of cigarettes in an effort to reduce smoking prevalence and smokingrelated disease (111th Congress, 2009; Gottlieb & Zeller, 2017). However, data have
suggested that OM smokers may experience a unique response to nicotine including
heightened reinforcement and potentially more severe withdrawal when stopping smoking
(Chait & Griffiths, 1984; Story & Stark, 1991; Weinberger et al., 2010). Thus, it is critical
to understand the extent to which reduced nicotine cigarettes may attenuate tobacco
withdrawal severity in this vulnerable smoker group as this has direct implications for the
potential acceptability and uptake of reduced nicotine cigarettes in OM smokers.
Across usual brand and reduced nicotine cigarettes, tobacco withdrawal and
craving did not differ as a function of OM status. While these results are inconsistent with
our hypotheses that OM status would moderate the relationship between nicotine dose and
withdrawal severity, they are consistent with our recent study examining tobacco
withdrawal severity in OM vs. non-SUD smokers in which no differences in withdrawal
or craving severity were observed between groups across a 2-week period of
biochemically-verified smoking abstinence (Streck et al., 2018).
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Whereas the prior

investigation examined individuals who quit smoking their usual brand cigarettes for a 2week study period, the current study further extends that work by including an evaluation
of multiple nicotine doses, rigorous double-blind conditions, and smokers who were not
currently interested in quitting smoking. The finding that OM smokers did not experience
greater tobacco withdrawal or craving relative to other vulnerable populations without
concurrent opioid dependence suggests that a national nicotine reduction policy would not
produce untoward withdrawal-related effects in this important smoker group.
In exploratory analyses, we also examined several other characteristics reflective
of smoking vulnerability (e.g., depression, nicotine dependence, educational attainment)
and their contributions to tobacco withdrawal and craving severity.

Generally, the

strongest predictor of both withdrawal and craving was baseline depression, with clinically
meaningful depression at study intake consistently associated with increased withdrawal
and craving across all nicotine doses. Once again, OM status did not exert a meaningful
influence on withdrawal or craving when accounting for other vulnerabilities. These
findings are consistent with prior research showing elevated incidence and severity of
tobacco withdrawal among smokers with affective disorders, particularly depression
(Covey et al., 1990; Morrell et al., 2008; Pomerleau et al., 2000; Smith et al., 2014;
Weinberger et al., 2010). Also worth noting is that negative affect is a strong contributor
in both depression and tobacco withdrawal (Tonkin et al., 2018), and depressed
mood/sadness is an item on the MTWS. Our data are also consistent with the only other
prior study to our knowledge which has examined the effects of depressive symptoms on
tobacco withdrawal in response to RNCCs (Tidey et al., 2017). In that study, which was
conducted with generally healthy smokers, while there were no interactions between
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nicotine dose and depression on withdrawal, greater withdrawal severity was observed
across nicotine doses in participants with higher levels of depression. Overall, given the
high rates of concomitant depression and other psychiatric disorders among OM patients
(Barry et al., 2016; Kidorf et al., 2004; Strain, 2002), these findings may hold clinical
significance for efforts to tackle smoking cessation among OM patients with co-occurring
psychiatric distress. However, also important to note is that we did not see an additive
effect on withdrawal severity of OM status and depression in this study. This is actually
consistent with a prior report using nationally-representative data to examine the effects of
having a co-morbid psychiatric disorder and SUD compared to a psychiatric disorder alone
on tobacco withdrawal (Weinberger et al., 2010). In that study, while the presence of a
SUD and a non-SUD psychiatric disorder were each independently associated with
increased presence and severity of withdrawal symptoms, the two types of disorders did
not act additively to increase withdrawal symptoms. That study did not examine the effects
of OUD specifically.
Several comments are warranted on the other characteristics examined during the
exploratory Aim 3 analyses. First, in the multivariable models, anxiety was not a final
significant predictor of withdrawal once depression was added to the model. Prior studies
have demonstrated an association between anxiety and increased incidence and severity of
tobacco withdrawal (Breslau et al., 1992; Morrell et al., 2008; Weinberger et al., 2010;
Zvolensky et al., 2008). It is possible that the instrument selected to measure anxiety in
this study (i.e., OASIS) may have been less sensitive than those used in prior studies on
this topic. For example, while the OASIS is a widely used and accepted screening measure
for anxiety, the four studies above demonstrating a significant association between anxiety
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and tobacco withdrawal used other measures (e.g., Anxiety Disorders Interview Schedule,
National Institute of Mental Health Diagnostic Interview Schedule). Thus, it is possible
that future studies evaluating anxiety and RNCC-associated withdrawal severity in OM
smokers with other instruments may find a more robust association.
Second, lower educational attainment was associated with more severe tobacco
withdrawal across nicotine doses. Limited educational attainment has been identified as
an important proxy for socioeconomic disadvantage (Shavers, 2007) and is associated with
increased prevalence of smoking and smoking-related adverse consequences (Agaku,
King, Dube, & Centers for Disease Control and Prevention, 2014; Jamal, 2016; King,
Dube, & Tynan, 2012). Several prior reports have hypothesized that withdrawal may be
greater among those with socioeconomic disadvantage more generally (Harwood et al.,
2007; Hiscock et al., 2012; Marmot & Wilkinson, 2005; Wiltshire et al., 2003), though we
are aware of only two empirical investigations on this topic. In the first study, Breslau and
colleagues examined epidemiological data from young adults in one state and found no
effects of education level on tobacco withdrawal (Breslau et al., 1992). In the second,
which was conducted in Syria, the authors reported that higher educational attainment was
associated with lower withdrawal scores among patients enrolled in a smoking cessation
trial (Ben Taleb et al., 2016). To our knowledge, the present study is the first to report on
the potential role of educational attainment on tobacco withdrawal in response to RNCCs.
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4.2. Limitations and Strengths
Several limitations of this study are important to note. First, we utilized an acute
exposure paradigm wherein participants abstained from smoking for 6-8 hours (versus
12-hour abstinence or longer), sampled each dose research cigarette during one
laboratory session, and rated their withdrawal across one hour post-smoking (versus days
or weeks). As such, we did not examine the full timecourse of tobacco withdrawal during
extended exposure, but rather the extent to which RNCCs may attenuate tobacco
withdrawal severity under conditions of acute abstinence. These acute-exposure data
support the feasibility of a national nicotine reduction policy in OM and other vulnerable
populations. However, additional extended exposure studies are needed to determine if
our results generalize to a longer timecourse of withdrawal under conditions of extended
abstinence and prolonged exposure to these reduced nicotine cigarettes.

We are

positioned to contribute new information on this question in the near future as we have
an extended exposure (i.e., 12-week) trial currently underway examining the longer-term
effects of RNCCs in OM and other vulnerable smoker populations. A recent publication
of a similar extended exposure trial in generally healthy smokers reported mild and
temporary increases in certain withdrawal symptoms with the extended use of RNCCs
(i.e., anger, irritability, frustration, increased appetite), but that these symptoms resolved
by 6 weeks (Dermody et al., 2018). Our forthcoming experimental study will extend
upon these prior findings to specifically address withdrawal in response to extended
exposure to RNCCs among vulnerable smokers.
Second, to be eligible for the present study, participants were required to be stable
in their opioid treatment, with limited opioid medication dose changes or illicit drug use.
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It is possible that a less stable population with OUD, such as those not currently receiving
treatment, may not respond as favorably to the RNCCs and that question merits further
investigation. A large number of individuals with OUD are not currently enrolled in
opioid treatment (Saloner & Karthikeyan, 2015), and one study has reported higher levels
of nicotine dependence and less motivation to quit among smokers not in opioid
maintenance treatment (and actively using intravenous opioids) compared to those
receiving treatment (Clarke et al., 2001). As we observed a positive relationship between
nicotine dependence and tobacco withdrawal in response to RNCCs, it is possible that
smokers with OUD who are not stable in opioid treatment may experience greater
withdrawal, though this is an empirical question that should be addressed more
definitively in future studies.
Third, this was a secondary analysis of data from a study that was not originally
designed or intended to examine outcomes as a function of OM status; that is, the
participant sample that was recruited for the parent study did not involve equal numbers
of OM and NOM smokers or comparable sociodemographic characteristics (e.g., gender)
across OM groups.

Although, we controlled for various sociodemographic

characteristics that differed by OM status in multivariable analyses, that does not rule out
the presence of other potential confounders. Additionally, as the parent trial was entirely
focused on understanding RNCC response among smokers with concomitant
vulnerabilities (e.g., anxiety/depression, socioeconomic disadvantage), there was no
control group of ‘healthy’ smokers without these co-occurring factors in the present
analyses.
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This study also had several important strengths. First, this is the only study to
date, to our knowledge, to rigorously evaluate tobacco withdrawal in response to RNCCs
in OM smokers. Second, study methodology included a rigorous, double-blind, highly
controlled design, multiple nicotine doses, availability of multiple empirically-supported
measures reflecting vulnerability to smoking, and minimal missing data or attrition.
Third, it also is the first study to investigate the separate and combined effects of multiple
co-occurring

vulnerabilities

(e.g.,

opioid

dependence,

depression,

anxiety,

socioeconomic disadvantage) and their impact on tobacco withdrawal severity in
response to RNCCs. Finally, this investigation is uniquely positioned to inform the
FDA’s decision making around reduced nicotine content cigarettes and their safety and
acceptability in vulnerable smoker populations as it moves toward the potential
implementation of a national nicotine reduction policy.

4.3. Conclusions
Despite prior data suggesting that OM smokers may respond differently to
nicotine and experience more severe withdrawal during reductions in nicotine intake,
opioid-maintained smokers in this study responded favorably to reduced nicotine content
cigarettes. Specifically, under the conditions of acute exposure and abstinence evaluated,
OM smokers did not experience more severe levels of tobacco withdrawal or craving
relative to vulnerable smokers without concurrent opioid dependence.

Depression

severity, rather than opioid dependence, was the strongest and most consistent predictor
of withdrawal and craving severity among the characteristics examined. These findings
provide additional support for the potential beneficial effects of a national nicotine
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reduction policy for reducing the burden of smoking and smoking-related consequences
among smokers with concurrent opioid dependence.
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Table 1
Prior Studies Examining Effects of Reduced Nicotine Content Cigarettes on Tobacco
Withdrawal
Study

Sample

Methods

Tobacco Withdrawal Results

Benowitz et
al., 2007

20 healthy
adult
smokers

Withdrawal increased during
the nicotine taper from baseline
to Week 6

Donny et al.,
2007

30 healthy
adult
smokers

Hatsukami et
al., 2010

165
healthy
adult
smokers
of light
cigarettes
235
healthy
adult
smokers

10-week outpatient study,
within-in subjects design,
participants smoked usual
brand and cigarettes with 12,
8, 4, 2 or 1 mg/g tobacco
11-day inpatient study,
between-subjects design,
random assignment to
cigarettes with 0.6 or, 0.05
mg of nicotine or a no
smoking condition
6-week outpatient study,
between-subjects design,
random assignment to 0.05 or
0.3 mg yield cigarettes or 4
mg nicotine lozenge
6-week outpatient study,
between-subjects design,
random assignment to 0.050.09 mg nicotine yield
cigarettes, 21 mg patch or
0.05-0.09 mg cigarettes with
21 mg patch,
all groups received 6 weeks
of behavioral treatment
6-week longitudinal
outpatient study, betweensubjects design, random
assignment to usual brand
cigarette or one of 6 types of
research cigarettes ranging
from 15.8 mg/g of tobacco to
0.4 mg/g

Significant differences between
groups with RNCCs+Patch
group having lower withdrawal
vs. Patch Alone

Hatsukami et
al., 2013

Donny et al.,
2015

840
healthy
adult
smokers
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No significant differences in
withdrawal between the groups

The 0.05 mg cigarette was
associated with reduced
withdrawal whereas 0.3 mg was
associated with increased
withdrawal vs. other products

Cigarettes with 5.2 mg/g or less
(vs. 15.8) did not significantly
increase peak daily withdrawal
during Weeks 1 or 6. Across the
6 weeks, there were no
significant differences in
withdrawal by dose.

Table 2
Baseline Demographic and Smoking Characteristics by Opioid-Maintenance Status

N
Demographics
Age
Female (%)
White (%)
Education (%)
<High school
High school
degree/equivalent
Some college
Associate degree or higher
Employment (%)
Full-time work
Part-time work
Casual employment
Unemployed
Other
Marital Status (%)
Never married
Married
Divorced or separated
Widowed
Smoking Characteristics
Cigarettes/day
Intake CO level
Age started smoking regularly
FTCD total score
Menthol smoker (%)
Psychiatric Characteristics
BDI total score
OASIS total score

All

OpioidMaintained (OM)

Non OpioidMaintained (NOM)

200

65

135

35+12
72
76

41+11
60
72

32+10
78
77

14

18

12

35
40
12

35
37
9

34
41
13

p value

<.001
.01
.07
.57

<.001
25
16
8
27
25

15
9
8
23
45

30
19
8
28
16

61
16
21
3

52
9
34
5

65
19
14
1

16+7
22+11
16+4
4.9+2
35

16+6
23+12
16+5
5.3+2
35

15+8
21+11
16+3
4.7+2
34

.06
.33
.29
.03
.87

12+11
6+5

8+8
3+3

14+13
7+6

<.01
<.001

<.01

Opioid Treatment Characteristics
Methadone maintained (%)
58
Methadone dose, mg
97+30
Buprenorphine dose, mg
14+9
Note. Mean + standard deviation unless otherwise noted; Bolded values represent p<.05; BDI, Beck
Depression Inventory (Beck, 1996); OASIS, Overall Anxiety Severity and Impairment Scale (Norman et
al., 2006); FTCD, Fagerström Test for Cigarette Dependence (Fagerström, 2012).
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Table 3
Multivariable Models Predicting MTWS Total Scores at the Baseline Usual Brand
Session (Session 1) and in Response to Cigarettes Varying in Nicotine Content
(Sessions 2-5)
Final models (All significant predictors)
Variable
Time
BDI
FTCD

Dose
Time
Dose x Time
BDI
Education
FTCD

F value
Session 1

p value

52.80
39.69
10.36

<.001
<.001
<.01

Sessions 2-5
3.65
97.30
3.00
28.23
3.08
9.34

.01
<.001
<.001
<.001
.03
<.01

Final models (All significant predictors with
OM status forced in)
Variable
F value
p value
Session 1
Time
52.80
<.001
BDI
43.98
<.001
FTCD
9.01
<.01
OM Status
2.62
.11
Sessions 2-5
Dose
3.65
.02
Time
97.30
<.001
Dose x Time
3.00
<.01
BDI
36.94
<.001
Education
3.23
.03
FTCD
5.98
.02
Race
3.41
.04
OM Status
6.65
.01

Table 4
Multivariable Models Predicting MTWS Desire to Smoke at the Baseline Usual
Brand Session (Session 1) and in Response to Cigarettes Varying in Nicotine
Content (Sessions 2-5)
Final models (All significant predictors)
Variable
Time
BDI
FTCD
CO level

F value
Session 1
62.82
6.22
26.39
9.6

p value
<.001
.01
<.001
<.01

Sessions 2-5
Dose
Time
Dose x Time
FTCD
OM status

8.77
130.93
6.42
32.09
0.88

<.001
<.001
<.001
<.001
.35

Final models (All significant predictors with
OM status forced in)
Variable
F value
p value
Session 1
Time
62.82
<.001
BDI
6
.02
FTCD
25.54
<.001
CO level
9.46
<.01
OM status
0.04
.84
Sessions 2-5
Dose
8.77
<.001
Time
130.93
<.001
Dose x Time
6.42
<.001
FTCD
32.09
<.001
OM status
0.88
.35
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Time x OM status

3.34

.01

Time x OM status

3.34

.01

Table 5
Multivariable Models Predicting MTWS Total and Desire to Smoke AUC Scores at
the Baseline Usual Brand Session and in Response to Cigarettes Varying in
Nicotine Content
MTWS Total Score AUC
Final models (All significant predictors)
Variable
BDI
FTCD

Dose
BDI
FTCD
Education
OM status

F value
Session 1

p value

38.22
12.10

<.001
<.01

Sessions 2-5
3.85
36.70
6.71
3.42
5.58

<.01
<.001
.01
.02
.02

Final models (All significant predictors with
OM status forced in)
Variable
F value
p value
Session 1
BDI
41.14
<.001
FTCD
10.26
<.01
OM status
2.61
.12
Sessions 2-5
Dose
3.85
<.01
BDI
36.70
<.001
FTCD
6.71
.01
Education
3.42
.02
OM status
5.58
.02

MTWS Desire to Smoke AUC
Final models (All significant predictors)
Variable
BDI
FTCD
CO level

F value
Session 1
5.78
26.80
8.21

p value
.02
<.001
<.01

Sessions 2-5
Dose
FTCD

10.55
34.83

<.001
<.001

Final models (All significant predictors with
OM status forced in)
Variable
F value
p value
Session 1
BDI
5.79
0.02
FTCD
25.74
<.001
CO level
8.04
<.01
OM status
0.12
.73
Sessions 2-5
Dose
10.55
<.001
FTCD
32.75
<.001
OM status
0.94
.33
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Table 6
Baseline Demographic and Smoking Characteristics of Phase 1 Completers vs.
Noncompleters

N
Demographics
Age
Female (%)
White (%)
Education (%)
<High school
High school
degree/equivalent
Some college
Associate degree or higher
Employment (%)
Full-time work
Part-time work
Casual employment
Unemployed
Other
Marital Status (%)
Never married
Married
Divorced or separated
Widowed

All

Phase 1 Completer

Noncompleter

235

200

35

34 ± 12
73
77

35± 11
72
75

31 ± 12
77
86

13

14

6

37

34

5

39
11

40
11

34
9

27
14
8
27
24

25
15
8
26
25

40
3
6
31
20

62
14
22
2

61
16
20
2

66
6
29
0

p value

.10
.68
.23
.27

.14

.29

Smoking Characteristics
Cigarettes/day
16 ± 7
15 ± 7
18 ± 7
.05
Intake CO level
22 ± 11
22 ± 11
21 ± 10
.81
Age started smoking regularly
16 ± 4
16 ± 4
16 ± 3
.35
5±2
5±2
5±2
.59
FTCD total score
Menthol smoker (%)
34
34
31
.85
Note. Mean + standard deviation unless otherwise noted; Continuous variables were tested using the
Student’s t-test; Categorical variables were tested using Fisher’s Exact Test; Bolded values represent
p<.05.
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Withdrawal in Response to the Cigarettes Varying in Nicotine Content
MTWS Total Score
12
10

AUC

8
6
4
2
0
0.4

2.4

5.2

15.8

Nicotine Dose, mg/g
Economically Disadvantaged Women

Opioid-Maintained

Affective Disorders

Figure 1. MTWS Total AUC scores from the parent study (Higgins et al., 2017),
presented across nicotine doses by study sub-sample
Note. Error bars represent standard error of the mean.
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General Study Inclusion
Criteria:
• >18 years old
• Smoking > 5 cigarettes/day
for past year
• Breath carbon monoxide > 8
particles/million

1. Socio-economically
Disadvantaged Women:
• Women
• 18 – 44 years old
• < Associates degree

2. Opioid-Maintained:
• 18-70 years old
• Receiving methadone or
buprenorphine maintenance
• Stable on maintenance dose
• No changes in dose in
past 30 days
• <30% samples positive
for illicit drugs in past 30
days

3. Affective Disorders:
• 18-70 years old
• Current DSM-IV diagnosis
for anxiety or depressive
disorder

Figure 2. Inclusion criteria for the parent study sub-samples
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Start of Session
• Arrive after 6-8 hours
of abstinence (< 50%
of intake CO)
• 2 puffs of usual brand
cigarette to equate
time since last
smoked
• 30-min wait period

Pre-Cigarette
Questionnaires

Smoking
• 1 research cigarette
smoked ad-libitum

• MTWS

Post-Cigarette
Questionnaires
• MTWS (Completed
+15, +30, +45, +60
minutes after
smoking)

Figure 3. Overview of experimental procedures during baseline (Session 1) and Study
Phase 1 (Sessions 2-5).
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Withdrawal and Craving in Response to the Usual Brand
Cigarette
4

MTWS Total Score

Mean

3

Opioid-Maintained
Non Opioid-Maintained

2
1
0
Pre-Smoking
Baseline

+15 min

+30 min

+45 min

+60 min

MTWS Desire to Smoke

4

Mean

3
2
1
0
Pre-Smoking
Baseline

+15 min

+30 min

+45 min

+60 min

Time

Figure 4. MTWS Total and Desire to Smoke scores at the baseline session across time by
OM status
Note. Error bars represent standard error of the mean.
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12

Withdrawal and Craving in Response to the Cigarettes Varying in
Nicotine Content
MTWS Total Score

10

Opioid-Maintained

AUC

8

Non Opioid-Maintained

6
4
2
0
0.4

2.4

5.2

15.8

MTWS Desire to Smoke

12
10

AUC

8
6
4
2
0
0.4

2.4

5.2

15.8

Nicotine Dose (mg/g)

Figure 5. MTWS Total and Desire to Smoke AUC scores across nicotine dose by OM
status
Note. Error bars represent standard error of the mean. To ease interpretation of Aim 2 data involving
multiple nicotine doses and timepoints, AUC data are presented.
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